Filing summary
Entity and period: The request metadata identifies Solana Co and 2015 Q1, but the supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the three months ended June 30, 2015, filed August 14, 2015. The summary below reflects the filing; the entity and period discrepancy should be verified.
Business context
Helius is a pre-revenue medical technology company developing the PoNS device, a non-invasive neuromodulation technology intended to support rehabilitation for neurological disorders. The quarter’s work included device development and clinical-trial preparation. The filing reports no product or service revenue.
Financial performance and position
- Revenue: $0 for the quarter, unchanged from the comparable 2014 quarter. Gross margin is not meaningful because the company reported no revenue.
- Operating expenses: $2.835 million, versus $1.389 million a year earlier. Research and development was $1.387 million, up from $653,259; the filing attributes much of the increase to PoNS development, clinical-trial preparation, the Ximedica program, and a NeuroFeedback pilot trial.
- Net loss: $3.095 million, compared with $1.569 million; basic and diluted loss per share was $0.05 versus $0.04. Comprehensive loss was $3.054 million, including $40,626 of translation income.
- Cash flow: Operating activities used $2.146 million, compared with $540,868 in the prior-year quarter. Financing provided $2.395 million, principally from private placements; investing activities provided $378,000 as short-term investments were liquidated. Ending cash was $971,863, up from $418,893 at March 31, 2015.
- Liquidity: Current assets were $1.430 million and current liabilities were $1.583 million, resulting in a $153,160 working-capital deficit, compared with $18,543 of working capital at March 31. Prepaid expenses included a $300,000 Ximedica prepayment.
- Debt and other liabilities: The balance sheet reported no conventional debt balance. A $1.846 million derivative liability, related to non-employee stock options, was remeasured through earnings; its fair-value change produced a $178,378 loss. Accounts payable and accrued liabilities were $1.583 million.
Changes, outlook, and risks
- Loss widened year over year as the company expanded spending, including on R&D, wages and salaries, advertising and investor relations, legal work, and travel. A foreign-exchange loss of $81,425 also compared with $6,446 in the prior-year quarter.
- The company stated that its cash resources were insufficient for operating and capital needs for the ensuing fiscal year and that, without additional financing, resources would not be sufficient through the third quarter of 2015. Management planned to seek additional equity or debt financing; it warned that unavailable financing could force reduced operations or asset sales. The filing states that this uncertainty raises substantial doubt about the company’s ability to continue as a going concern.
- After quarter-end, the company raised $270,375 gross in a July 17 private placement, issuing units with common shares and warrants. This subsequent financing does not remove the stated funding risk.
- Product commercialization depended on completing device design, obtaining FDA clearance, manufacturing a commercially viable device, and demonstrating effectiveness sufficient to attract orders. The filing gives no specific commercialization date or financial guidance.
- A lawsuit filed in May 2015 seeks monetary damages in excess of $225,000 over alleged breach of a consulting arrangement and use of business and marketing plans. Management said it could not determine the outcome; the company intended to defend the case.
- Management found disclosure controls and procedures ineffective at June 30, 2015, citing insufficient technical accounting expertise in income taxes and complex U.S. GAAP matters. Remediation was in progress, subject to resources becoming available.
- The company reported no material changes to the risk factors in its fiscal 2015 Form 10-K. It also noted exposure to foreign-exchange fluctuations and no currency hedging.
Important facts for investors to verify
- Confirm the filing issuer and reporting period: the supplied document is Helius Medical Technologies’ June 30, 2015 10-Q, not a Solana Co filing.
- Assess funding runway and the availability, timing, and terms of further capital; compare the stated runway with the July 2015 financing and subsequent cash needs.
- Track PoNS development, clinical evidence, regulatory progress, manufacturing readiness, and any path to revenue.
- Review the status and potential exposure of the lawsuit, and the remediation of ineffective disclosure controls.
- Reconcile financing cash flow: the cash flow statement reports $2,394,684, while the MD&A narrative reports $2,434,229 for the quarter.